Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings (ARCT) has 3 years of Total Non-Current Liabilities data on file, last reported at $150.4 million in Q4 2023.

• Quarterly Total Non-Current Liabilities fell 15.16% year-over-year to $150.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $150.4 million (down 15.16% YoY) and the FY2023 annual result came in at $150.4 million, down 15.16% from the prior year.
• Total Non-Current Liabilities eased to $150.4 million in Q4 2023, from $176.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $177.3 million in Q4 2022 to a low of $128.5 million in Q1 2021.
• A 3-year average of $153.0 million and a median of $144.3 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 17.09% — and 2023, when it climbed 22.41%.
• Tracing ARCT's Total Non-Current Liabilities over 3 years: stood at $174.0 million in 2021, then gained by 1.87% to $177.3 million in 2022, then declined by 15.16% to $150.4 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $150.4 million (Q4 2023), $176.6 million (Q3 2023), and $144.2 million (Q2 2023), per Business Quant data.